Built by someone who lived the problem.

Two decades in healthcare. One clear conviction.

Ryan Bell has spent more than two decades in healthcare across many hospital systems, operating across the full continuum of hospital roles. He has consulted for medical device and healthcare technology companies, participated in health system financial strategy, held P&L responsibility for portfolios representing hundreds of millions in revenue - and has sat on both sides of the table when capital decisions are made.

That vantage point exposed a pattern that repeated itself too often: promising medical technologies failing - not in clinical trials, but in the pitch, at the Value Analysis Committee, and ultimately in the market. The root cause was rarely the device itself. It was the absence of a shared financial lens that could translate clinical value into the economic language that CFOs, supply chain leaders, and VAC members need to approve a purchase.

Device manufacturers would launch products without understanding where their technology fit within a hospital's DRG economics, reimbursement corridors, or existing cost structure. Hospitals would evaluate new technology against incomplete data - often relying on vendor-supplied projections that couldn't survive a rigorous financial review. The result: delayed decisions, missed adoption windows, and billions left on the table across the industry every year.